Cellectar Biosciences Announces Phase 2 CLOVER-WaM Study Data Selected for Presentation at ASH Meeting and Financial Results for Q3 2024
Cellectar Biosciences announced Phase 2 study results and fundraising efforts, preparing for NDA submission for iopofosine I 131.Quiver AI SummaryCellectar Biosciences, Inc. announced significant advancements...
Cellectar Reports Financial Results for Second Quarter 2022
FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the...
Cellectar Announces Stock Consolidation
FLORHAM PARK, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the...
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...